Ginkgo Biloba

Introduction: Research indicates that Physiological stress leads to tissue and cellular damage through its disruPtion of antioxidant status in the body. The main objective of this research was to determine the effects of 12 weeks of high-intensity functional training (HIFT) and Ginkgo biloba (Gb) suPPlementation on suPeroxide dismutase (SOD), catalase (CAT) and total antioxidant caPacity (TAC) serum levels in male firefighters of the oPerational division of Yazd City. Methods: In this semi-exPerimental study, 48 male firefighters were randomly divided into four grouPs: high-intensity functional training (HIFT), high-intensity functional training combined with ginkgo biloba suPPlementation (HIFT+Gb), ginkgo biloba extract alone (Gb), and a control Placebo grouP (P-C). The training Program lasted 12 weeks, with ParticiPants training four times Per week. The ginkgo biloba suPPlement (80 mg) was administered in two caPsules daily after breakfast for the entire 12-week Period. Blood samPles were taken before the start and 48 hours after the last training session. The collected data were analyzed using rePeated measures ANOVA, as well as one-way and two-way ANOVA in SPSS version 16. Results: After 12 weeks of intervention, SOD, CAT, and TAC in the HIFT (P=0.0001), HIFT+Gb (P=0.0001), and Gb (P=0.0001) grouPs showed a significant increase comPared to the P-C grouP. SOD, CAT, and TAC levels in the HIFT (P=0.0001) and HIFT+Gb (P=0.0001) grouPs significantly rose when comPared to the Gb grouP. SOD, CAT, and TAC levels in the HIFT grouP (P=0.0001) were notably elevated in comParison to the HIFT+Gb grouP. The synergistic influence of HIFT with Gb markedly elevated serum concentrations of SOD, CAT, and TAC (P<0.05). The greatest Percentage of alterations in SOD, CAT, and TAC were noted after the HIFT intervention with Gb Conclusion: The combined imPact of 12 weeks of HIFT Paired with Ginkgo biloba intake, in comParison to the individual effect of each, significantly enhanced

Neurodegenerative conditions like anxiety, depression, and Alzheimer's disease can result from prolonged exposure to stress. Herbal supplements like Ginkgo biloba and Curcuma longa (turmeric) are being investigated as a result of the search for natural neuroprotective agents. In order to mitigate streptozotocin-induced neurodegeneration, this study examined the effects of combining ginkgo biloba supplements with Curcuma longa root extract. Twenty-five rats weighing between 90 and 120 grammes were split into five groups of five animals each. Group A was the control group; Group B was the negative control group (STZ alone); and Groups C–E were given extracts orally for 21 days at doses of 50, 100, and 150 mg/kg of Ginkgo biloba supplement and 200, 400, and 500 mg/kg of turmeric root extract. Following daily extract administration, a neurobehavioral test was performed. After 21 days, the animals were sacrificed and blood was extracted via ocular puncture into an EDTA container, and the serum was separated for oxidative biomarker analysis by centrifugation. The brain hippocampus was extracted and homogenized to measure the hippocampus absorbance level. Ginkgo biloba supplement and Curcuma longa root extract, at the doses tested on the Group C-E, significantly decreased p≤0.05 MDA, while GSH and SOD significantly increased p≤0.05 compared to group B. The hippocampus absorbance level increased non-significantly when compared to B. When comparing the test group to group B, there was a notable improvement in spatial memory and cognitive function, as evidenced by the significant decrease in escape latency and the number of errors (p≤0.05) and the significant increase in path efficiency. This study implies that some neurodegenerative diseases in diabetic rats may be lessened by the combined application of Curcuma longa roots and Ginkgo biloba supplements.

PURPOSE: This study aims to explore the effect of Ginkgo biloba extracts (GbE) on the prevention of posterior capsule opacification (PCO). STUDY DESIGN: This study was a double-blinded, placebo-controlled, single-center randomized clinical trial. METHODS: Patients with senile cataracts randomly received GbE supplement capsules at a dose of 200 mg (n = 74) or an identical placebo (n = 70) daily for 6 months after cataract surgery. Patients’ follow-ups were scheduled for up to 3 years after cataract surgery. PCO formation (Pearl/Fibrotic) was graded using slit-lamp examinations. The necessity of a Neodymium-doped yttrium aluminum garnet (Nd: YAG) laser capsulotomy was evaluated by patients’ complaints of reduced visual acuity imputable to PCO. RESULTS: A total of 144 patients with a mean age of 64.92 ± 7.77 years were studied. The mean Log MAR visual acuity in the placebo group started to decrease at 12 months (P = 0.003) and remained significantly lower than the GbE group throughout 36 months (P = 0.005). At 1-year postsurgery, a significant difference between the two groups of GbE and Placebo was observed regarding pearl PCO score, but obvious fibrotic PCO score differences occurred 3 years after surgery. The Nd: YAG capsulotomy was performed in six eyes (6.1%) for the GbE group and 18 eyes (20.4%) for the placebo group (P = 0.004) 3 years after the cataract surgery. CONCLUSION: Six months of supplementation with GbE was well tolerated and may provide some marginal prevention in the PCO formation. Besides the effect of the GbE in the inhibition of PCO, we also observed a noticeable reduction in the need for Nd: YAG laser capsulotomy.

The aim of this study is to present the formulation of MyExosome®, an innovative, fully organic, and vegan functional food supplement containing orally consumable EPDEN’s (edible plant-derived exosome-like nanoparticles), designed to combat and preventive Alzheimer’s disease and dementia. This formulation is produced using EPDEN’s derived from organic Coffea arabica seeds, organic Ginkgo biloba leaves, and organic Panax ginseng root-rhizomes, all of which are known for their neuroprotective properties. The isolation of these nanoparticles and the formulation of MyExosome® were optimized at the AYE Exocure R&D Center. MyExosome®’s preventive and therapeutic effects against Alzheimer’s have been proven in in-vitro (Alzheimer’s model and microglial cells), in-vivo (Alzheimer’s model rats), and clinical studies conducted by AYE Exocure. Our goal is to enhance the stability, selectivity, sensitivity, and specificity of these nanoparticles, providing an effective support to slow down or prevent the progression of neurodegenerative diseases.

Cardiovascular diseases, among which arterial hypertension (AH) occupies a priority place, are independent risk factors for the development and progression of cognitive disorders. The primary strategy in the prevention of dementia remains the correction of cardiovascular risk factors, as well as the search for additional approaches to prevent the development and progression of cognitive dysfunction with the involvement of neuroprotective and vasoprotective therapy. The objective: to evaluate the effect of a fixed combination (FC) of citicoline and ginkgo biloba (dietary supplement Axonal) on cognitive function indicators in patients with mild cognitive impairment (MCI) syndrome compared to monotherapy with citicoline or ginkgo biloba. Materials and methods. The research studied the dynamics of cognitive indicators in patients with AH, who took an FC of citicoline/ginkgo biloba (dietary supplement Axonal) and monotherapy with citicoline or ginkgo biloba for 90 days. A double-blind study enrolled 70 patients with MCI syndrome; their mean age at enrollment was 65.30 ± 5.54 years. All patients received treatment in accordance with the existing standards/protocols for providing medical care, approved by the Ministry of Health of Ukraine. Cognitive functions were assessed using the Montreal Cognitive Assessment Test (MoCA), Schulte tables, symbol-digit test and Stroop test. Results. Comparative analysis demonstrated the superiority of FC of citicoline/ginkgo biloba over the monotherapy group (citicoline or ginkgo biloba) in a significant increase in the MoCA integral test score by 11.4% (from 23.6 ± 1.5 to 26.3 ± 1.7 points, p < 0.001), restoration of cognitive functions in the domains of “executive skills” (0.33 ± 0.65 vs 0.26 ± 0.68 points, p = 0.03); “attention, counting” (0.09 ± 0.29 vs 0.01 ± 0.52 points, p = 0.01) and “memory, delayed repetition” (1.57 ± 1.51 vs 0.71 ± 1.51 points, p = 0.02) and improving the speed of information processing and concentration of a

Vitiligo is a progressive and multifactorial condition of skin, mucosa, and hair depigmentation. Loss of functional melanocytes leads to the appearance of white macules on the skin, often affecting the lips and genitalia. The impact extends to psychological stress, decreased quality of life, and risk of psychiatric morbidity. Various therapeutic strategies have been designed to inhibit the immune response in vitiligo to reduce melanocyte damage while increasing melanocyte repopulation. There is no standardized method of evaluating treatment outcomes in vitiligo patients. Herbal medicines several studies have shown that GB also has many benefits for health and healing skin diseases, one of which is used in treating vitiligo. Therefore, this study aimed to evaluate the potential of Ginkgo biloba extract as a therapeutic supplement in enhancing the positive effects of desoxymethasone on vitiligo. Using a double-blind randomized control trial clinical trial research design, 26 subjects were divided into treatment and control groups. The control group received standard vitiligo therapy with topical desoxymethasone and placebo, while the treatment group received topical desoxymethasone plus Ginkgo biloba extract. Melanin index, VASI score, MDA, TNF-α, CD8 expression, and caspase 3 were measured before and after treatment. The results showed that the administration of Ginkgo biloba extract had a significant effect in reducing MDA, TNF-α, CD8 expression, and caspase 3 levels, and improving melanin index and erythema in vitiligo patients who received topical desoxymethasone therapy. These findings demonstrate the positive potential of Ginkgo biloba extract as an adjunct to vitiligo therapy, resulting in favorable clinical and molecular impacts in patients undergoing combination treatments.

BACKGROUND Apoptotic and oxido-inflammatory pathways have been found to be up-regulated in lead acetate poisoning which has been associated to endothelial and testicular dysfunctions. It is yet uncertain, nevertheless, if treatment with Ginkgo biloba supplements (GBS), a flavonoid-rich natural product can lessen the adverse effects of lead on endothelial and testicular functions. This study investigated the impact of Ginkgo biloba supplementation on lead-induced endothelial and testicular dysfunctions. METHODS The animals were treated with GBS (50 mg/kg and 100 mg/kg orally) for 14 days following oral exposure to lead acetate (25 mg/kg) for 14 days. After euthanasia, blood samples, epididymal sperm, testes, and aorta were collected. The quantities of the hormones (testosterone, follicle stimulating hormone (FSH) and luteinizing hormone (LH), as well as the anti-apoptotic, oxidative, nitrergic, inflammatory markers, were then determined using immunohistochemistry, ELISA, and conventional biochemical methods. RESULTS GBS reduced lead-induced oxidative stress by increasing the levels of the antioxidant enzymes catalase (CAT), glutathione (GSH), and superoxide dismutase (SOD), while lowering malondialdehyde (MDA) in endothelium and testicular cells. Normal testicular weight was restored by GBS which also decreased endothelial endothelin-I and increased nitrite levels. TNF-α and IL-6 were decreased while Bcl-2 protein expression was enhanced. Lead-induced alterations in reproductive hormones (FSH, LH, and testosterone) were also restored to normal. CONCLUSION According to our result, using Ginkgo biloba supplement prevented lead from causing endothelial and testicular dysfunction by raising pituitary-testicular hormone levels, boosting Bcl-2 protein expression and lowering oxidative and inflammatory stress in the endothelium and testes.

Meta-analisis para acufenos. EGb 761 mostro beneficio modesto pero significativo en reduccion de tinnitus.

RCT con EGb 761 240mg/dia. Mejoro cognicion y sintomas neuropsiquiatricos en demencia.

Revision Cochrane. Evidencia inconsistente pero algunos estudios muestran beneficio en deterioro cognitivo con EGb 761.